Dr. Dong M. Shin, Emory Winship Cancer Institute

Dong M. Shin M.D.

Director, Clinical and Translational Cancer Prevention Program

Get in touch
  • Hematology and Medical Oncology

About Dr. Shin


  • Pleural and Lung Cancer icon

    Pleural and Lung Cancer

  • Research Excellence icon

    Excellence in Research

  • Team Leader icon

    Team Leader

  • Board Certified icon

    Board Certified in Medical Oncology

  • Board Certified icon

    Board Certified in Internal Medicine

Dong Moon Shin, M.D., is professor of Hematology, Oncology and Otolaryngology and Associate Director of Academic Development for the Emory Winship Cancer Institute, in Atlanta, Georgia. He is also the Director of the Emory Winship Cancer Institute Cancer Chemoprevention Program and Co-Director of the Center’s Lung and Aerodigestive Tract Malignancies Program.

A native of South Korea, Shin completed his medical training at the Yonsei University College of Medicine in Seoul, receiving his medical degree in 1975. He then served a four-year internship at Yonsei University Hospital and another four-year internship at Cook County Hospital in Chicago.

He completed his residency at Cook County in 1985 and followed that with a Fellowship in Hematology and Medical Oncology at the University of Texas, M.D. Anderson Cancer Center, in Houston, in 1988. He joined the faculty of the Winship Cancer Institute in 2003, after 15 years as a faculty member at the M.D. Anderson Center and the University of Pittsburgh.

Shin is the recipient of numerous awards, grants, and professional recognitions. He has published more than 150 peer-reviewed articles in prestigious medical journals, such as the Journal of the National Cancer Institute and The New England Journal of Medicine. His research is cited in hundreds of studies and articles. Shin is certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine. He is a member of the American Association for Cancer Research and is a Fellow of the American College of Physicians and the American Society of Head and Neck Surgery.

Talk to a Doctor About Your Diagnosis

We can help you or a loved one get in contact with Dr. Shin and find the treatment that's best for you.

Get Started Today

Focused on Research

Shin specializes in the study and management of mesothelioma and other cancers of the head, neck and lungs, and has worked for years to develop new treatment and prevention techniques.

He has done extensive research in:

  • Establishing carcinogenesis models in preclinical and clinical settings
  • Developing biomarkers in animal and human carcinogenesis for head, neck and lung cancer
  • Developing novel therapeutics and protocols for rarer cancers like mesothelioma and thymoma (cancer of the thymus gland)
  • The use of nanotechnology to deliver drugs to cancer patients

In 2003, a study conducted by Shin and others found positive results by treating pleural mesothelioma patients with a combination of chemotherapy and vitamin supplementation. Patients who received the drug, Pemetrexed with folic acid and vitamin B12 survived an average of five months longer than those who received Pemetrexed only.

In 2005, Shin began a phase III clinical trial of Vorinostat (suberoylanilide hydromaxic acid) for patients with advanced malignant pleural mesothelioma that has gotten worse despite having at least one type of chemotherapy. Vorinostat is believed to help stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The drug is marketed by Merck Pharmaceuticals as Zolinza, and is currently FDA-approved for the treatment of cutaneous T-cell lymphoma. The study was completed in November 2011, but no results are posted yet.



Disclaimer: Dr. Dong M. Shin has no professional affiliation with Asbestos.com.


Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Tim Povtak, Senior Content Writer at Asbestos.com

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

  1. U.S. National Institutes of Health. (2012, April 3). Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1). Retrieved from http://clinicaltrials.gov/show/NCT00128102
  2. Emory Winship Cancer Center. (n.d.). Dong M. Shin, MD, FACP. Retrieved August 24, 2012, from http://winshipcancer.emory.edu/find-a-physician/WinshipContentPage.aspx?nd=807&id=221&typ=33
  3. Emory University - Woodruff Health Sciences Center. (2005, December 22) Emory Winship Cancer Institute to Conduct Phase III Clinical Trial on Pleural Mesothelioma. Retrieved from http://whsc.emory.edu/press_releases2.cfm?announcement_id_seq=5421
  4. Emory University - Woodruff Health Sciences Center. (2005, December 22) Dong M. Shin, MD, Appointed to Associate Director of Emory Winship Cancer. Retrieved from http://whsc.emory.edu/press_releases2.cfm?announcement_id_seq=5420
  5. Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma. (2003, April 15). Journal of Clinical Oncology. Retrieved from http://jco.ascopubs.org/content/21/8/1556.full
  6. Dong M. Shin, MD, FACP. (n.d.). Retrieved August 23, 2012, from https://winshipcancer.emory.edu/bios/faculty/shin-dong-moon.html
Get Help Contacting Dong M. Shin

View our resources for patients and families

Get Help Today
Get Your Free Mesothelioma Guide